Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2053129 | 0.92 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL6423170 | 0.91 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP2C9KMT2AHSD17B10 | |
| SCHEMBL27750685 | 0.90 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2AHSD17B10TDP1 | |
| SCHEMBL6418597 | 0.85 | EPHX2 (0.35) | ALDH1A1CYP1A2CYP2C9HSD17B10TDP1 | |
| SCHEMBL2053130 | 0.82 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2AHSD17B10TDP1 | |
| SCHEMBL11484971 | 0.81 | HSD17B10 (0.52) | ALDH1A1MEN1KMT2AHSD17B10TDP1 | |
| SCHEMBL6420476 | 0.79 | HSD17B10 (0.43) | ALDH1A1CYP1A2CYP2C9KMT2AHSD17B10 | |
| SCHEMBL2784963 | 0.78 | MMP1 (0.42) | ALDH1A1CYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL6898652 | 0.77 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP2C9HSD17B10MMP1 | |
| SCHEMBL6898655 | 0.77 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP2C9HSD17B10MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2329821-B1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GLAXOSMITHKLINE LLC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1968594-B1 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | GLAXOSMITHKLINE LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20080293691-A1 | Treatment Method | SMITHKLINE BEECHAM CORPORATION | 2008-11-27 | — | — | US | disclosed |
| EP-1968594-A2 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007064752-A2 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6825188-B2 | MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN | SMITHKLINE BEECHAM CORPORATION | 2004-11-30 | — | — | US | disclosed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| EP-0946180-A4 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
| EP-0946180-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ALDH1A1 3956/4885CYP1A2 2551/4885CYP2C9 3226/4885 |
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | ALDH1A1 2599/4885CYP1A2 4457/4885CYP2C9 4808/4885 |
| US-20080293691-A1 | Treatment Method | ALDH1A2, KDR, VEGFA | ALDH1A1 166/4885CYP1A2 1666/4885CYP2C9 2557/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ALDH1A1 3956/4885CYP1A2 2551/4885CYP2C9 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.